Jan. 9, 2007 (China Knowledge) – Five potential investors have filed restructuring proposals for China's Sanjiu Enterprise Group, China's largest traditional Chinese medicine producer.

The five potential investors are a Deutsche Bank-led consortium, a Shanghai Industrial Investment Co. Ltd. consortium, a New World Group consortium, Fosun Group and China Resources Group. The company, which is under investigation by the China Securities Regulation (CSRC) for fund misappropriation issues, has not agreed to a deal with the potential investors, but is expected to select a partner before the end of the month.

Sanjiu Group is one of the 17 companies that are under investigation by the CSRC for failing to recover RMB 9.2 billion of debt by their controlling shareholders before the deadline CSRC had set.